Navigation Links
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Date:7/30/2008

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

"This patent represents an important component in the development of our intellectual property in peptide copolymers, including PI-2301," stated Thomas P. Mathers, President and CEO of Peptimmune. "The '790 patent protects what we believe may become a very important therapy for the treatment of multiple sclerosis and other autoimmune diseases."

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has put in place high-quality synthesis and analytical methods that provide a superior level of batch-to-batch reproducibility in the manufacturing of PI-2301.

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve-insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

The '790 patent claims "A linear random copolymer YFAK comprising amino acids tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K)," )." which was licensed from Harvard University. The copolymer technology was developed in conjunction with Professor Jack L. Strominger M.D., Higgins Professor of Biochemistry, Department of Molecular and Cellular Biology, at Harvard University. Peptimmune is the exclusive worldwide licensee of the '790 patent.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation. For additional information, please contact us.

For information please contact Tom Mathers at (617) 715-8000 or tom.mathers@peptimmune.com.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 FinancialBuzz.com News Commentary  ... According to new ... market research, the legal cannabis market is projected to continue ... conflicting signals from the current presidential administration. The report created ... biggest drivers of growth in this industry are the passage ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... The IPF pipeline is very strong with a total of 97 ... Inc., Biogen and Sanofi are involved in the development of the IPF ... is in Phase III stage, 15 are in Phase II stage, 12 ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com ... has been growing rapidly as the global sales of Adcetris and ... growth in the antibody drug conjugates market is driven by large ... cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF ... the greater Houston Area. The new location is located at 2255 E. Mossy Oaks ... Springwoods Village. This newest location will provide patients living in the north Houston area ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
(Date:3/23/2017)... , ... March 23, 2017 , ... 82% of adults are unaware of the dangers ... not brush their teeth the minimum two times a day that dentists recommend. The ramifications ... 51 million hours of school and adults missing 164 million hours of work each year ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
Breaking Medicine News(10 mins):